Tacrine | CAS#321-64-2 | Anticholinesterase

Tacrine
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318785

CAS#: 321-64-2

Description: Tacrine is a centrally acting anticholinesterase and indirect cholinergic agonist. It is approved for the treatment of Alzheimer's disease.

Chemical Structure

Tacrine

CAS# 321-64-2

Instruction

Theoretical Analysis

MedKoo Cat#: 318785
Name: Tacrine
CAS#: 321-64-2
Chemical Formula: C13H14N2
Exact Mass: 198.12
Molecular Weight: 198.269
Elemental Analysis: C, 78.75; H, 7.12; N, 14.13

Price and Availability

Size	Price	Availability	Quantity
1g	USD 250
2g	USD 450
5g	USD 650
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: CS 12602, CS 12602, CS 12602, Tacrine, Tacrinum, Tetrahydroaminocrine

IUPAC/Chemical Name: 1,2,3,4-tetrahydroacridin-9-amine

InChi Key: YLJREFDVOIBQDA-UHFFFAOYSA-N

InChi Code: InChI=1S/C13H14N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8H2,(H2,14,15)

SMILES Code: NC1=C(CCCC2)C2=NC3=CC=CC=C31

Appearance: White to off-white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 198.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Ismaili L, Refouvelet B, Benchekroun M, Brogi S, Brindisi M, Gemma S, Campiani G, Filipic S, Agbaba D, Esteban G, Unzeta M, Nikolic K, Butini S, Marco-Contelles J. Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease. Prog Neurobiol. 2016 Jan 18. pii: S0301-0082(15)00162-8. doi: 10.1016/j.pneurobio.2015.12.003. [Epub ahead of print] Review. PubMed PMID: 26797191.

2: Minarini A, Milelli A, Simoni E, Rosini M, Bolognesi ML, Marchetti C, Tumiatti V. Multifunctional tacrine derivatives in Alzheimer's disease. Curr Top Med Chem. 2013;13(15):1771-86. Review. PubMed PMID: 23931443.

3: Romero A, Cacabelos R, Oset-Gasque MJ, Samadi A, Marco-Contelles J. Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer's disease. Bioorg Med Chem Lett. 2013 Apr 1;23(7):1916-22. doi: 10.1016/j.bmcl.2013.02.017. Epub 2013 Feb 16. Review. PubMed PMID: 23481643.

4: Korábečný J, Spilovská K, Benek O, Musílek K, Soukup O, Kuča K. [Tacrine and its derivatives in the therapy of Alzheimers disease]. Ceska Slov Farm. 2012 Oct;61(5):210-21. Review. Czech. PubMed PMID: 23256654.

5: de Aquino RA, Modolo LV, Alves RB, de Fatima A. Design of new drugs for the treatment of Alzheimer's disease based on tacrine structure. Curr Drug Targets. 2013 Mar;14(3):378-97. Review. PubMed PMID: 23176115.

6: Tumiatti V, Minarini A, Bolognesi ML, Milelli A, Rosini M, Melchiorre C. Tacrine derivatives and Alzheimer's disease. Curr Med Chem. 2010;17(17):1825-38. Review. PubMed PMID: 20345341.

7: Jogani VV, Shah PJ, Mishra P, Mishra AK, Misra AR. Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting. Alzheimer Dis Assoc Disord. 2008 Apr-Jun;22(2):116-24. doi: 10.1097/WAD.0b013e318157205b. Review. PubMed PMID: 18525282.

8: Patocka J, Jun D, Kuca K. Possible role of hydroxylated metabolites of tacrine in drug toxicity and therapy of Alzheimer's disease. Curr Drug Metab. 2008 May;9(4):332-5. Review. PubMed PMID: 18473751.

9: Li WM, Kan KK, Carlier PR, Pang YP, Han YF. East meets West in the search for Alzheimer's therapeutics - novel dimeric inhibitors from tacrine and huperzine A. Curr Alzheimer Res. 2007 Sep;4(4):386-96. Review. PubMed PMID: 17908041.

10: Qizilbash N, Birks J, Lopez Arrieta J, Lewington S, Szeto S. WITHDRAWN: Tacrine for Alzheimer's disease. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD000202. Review. PubMed PMID: 17636619.

11: Summers WK. Tacrine, and Alzheimer's treatments. J Alzheimers Dis. 2006;9(3 Suppl):439-45. Review. PubMed PMID: 16914883.

12: Arrieta JL, Artalejo FR. Methodology, results and quality of clinical trials of tacrine in the treatment of Alzheimer's disease: a systematic review of the literature. Age Ageing. 1998 Mar;27(2):161-79. Review. PubMed PMID: 16296676.

13: Camps P, Muñoz-Torrero D. Tacrine-huperzine A hybrids (huprines): a new class of highly potent and selective acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease. Mini Rev Med Chem. 2001 Jul;1(2):163-74. Review. PubMed PMID: 12369981.

14: Qizilbash N, Birks J, Lopez Arrieta J, Lewington S, Szeto S. Tacrine for Alzheimer's disease. Cochrane Database Syst Rev. 2000;(3):CD000202. Review. Update in: Cochrane Database Syst Rev. 2007;(3):CD000202. PubMed PMID: 10908463.

15: Qizilbash N, Birks J, López-Arrieta J, Lewington S, Szeto S. Tacrine for Alzheimer's disease. Cochrane Database Syst Rev. 2000;(2):CD000202. Review. Update in: Cochrane Database Syst Rev. 2000;(3):CD000202. PubMed PMID: 10796507.

16: Proctor GR, Harvey AL. Synthesis of tacrine analogues and their structure-activity relationships. Curr Med Chem. 2000 Mar;7(3):295-302. Review. PubMed PMID: 10637366.

17: Kurz A. The therapeutic potential of tacrine. J Neural Transm Suppl. 1998;54:295-9. Review. PubMed PMID: 9850938.

18: Giacobini E. Invited review: Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications. Neurochem Int. 1998 May-Jun;32(5-6):413-9. Review. PubMed PMID: 9676739.

19: Conway EL. A review of the randomized controlled trials of tacrine in the treatment of Alzheimer's disease: methodologic considerations. Clin Neuropharmacol. 1998 Jan-Feb;21(1):8-17. Review. PubMed PMID: 9579280.

20: Ventura M, Sternon J. [Therapeutic results: tacrine]. Rev Med Brux. 1997 Dec;18(6):394-7. Review. French. PubMed PMID: 9481161.

Your view history

Tacrine featured